IFW

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;473840;1
AOC/RHU/jam
June 14, 2004

PATENT APPLICATION
DOCKET NO.: 1855.2036-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Kenneth G. Carson and Geraldine C. B. Harriman		
Application No.:	10/706,835	Group Art Unit:	1616
Filed:	November 12, 2003	Examiner:	Not assigned
Confirmation No.:	6925		
Title:	CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR		

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

6-14-04 Jane Morgan
Date Signature

JANE MORGAN
Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[ ] under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

[ ] under 37 CFR 1.97(c) together with either:

[ ] a Statement under 37 CFR 1.97(e), as checked below, or

[ ] a $180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[ ] under 37 CFR 1.97(d) together with:

[ ] a Statement under 37 CFR 1.97(e), as checked below, and

[ ] a $180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

[ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)
Applies to original applications (other than design) filed on or after May 29, 2000

[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[X] Copies of the cited references AL-AQ, AL2-AQ2, AL3-AQ3, AL4-AQ4, AL5-AQ5, AL6-AQ6, AL7-AQ7, AL8-AQ8, AL9-AQ9, AL10-AP10 and AR-AZ, AR2-AZ2, AR3-AZ3, AR4-AZ4 and AR5-AS5 are enclosed.

[X] Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

[ ] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

[X] References AC5 and AQ10 were cited in the enclosed International Search Report in a counterpart foreign application.

[X] The "concise explanation" requirement (non-English references) for references AO, AL3, AQ4, AL5, AO6, AP6, AQ6, AN7 and AO7 under 37 CFR 1.98(a)(3) is satisfied by:

[ ] the explanation provided on the attached sheet.

[ ] the explanation provided in the Specification.

[ ] submission of the enclosed International Search Report.

[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

[X] the enclosed English language abstracts.

[ ] Applicant requests that the following non-published pending applications be considered:

Examiner's Initials

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ _____

Examiner Date

[ ] A copy of each above-cited application, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of $[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Robert H. Underwood

Robert H. Underwood
Registration No.: 45,170
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: June 14, 2004

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1855.2036-001	10/706,835
	FIRST NAMED INVENTOR: Kenneth G. Carson	FILING DATE: November 12, 2003
June 14, 2004 (Use several sheets if necessary)	EXAMINER: Not assigned	CONFIRMATION NO.: 6925 / GROUP: 1616

OIPE JC105 JUN 16 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	3,770,729	11-06-1973	Nakanishi *et al.*
	AB	5,801,175	09-01-1998	Afonso *et al.*
	AC	4,250,176	02-10-1981	Vandenberk *et al.*
	AD	6,150,355	11-21-2000	Kumazawa *et al.*
	AE	5,877,177	03-02-1999	Taveras
	AF	4,645,758	02-24-1987	Willman *et al.*
	AG	4,335,122	06-15-1982	McFadden *et al.*
	AH	5,011,836	04-30-1991	Eberlein *et al.*
	AI	5,688,788	11-18-1997	Andersen *et al.*
	AJ	6,048,856	04-11-2000	Jørgensen *et al.*
	AK	6,040,318	03-21-2000	Andersen *et al.*
	AA2	5,538,986	07-23-1996	Ting *et al.*
	AB2	4,567,178	01-28-1986	Eberlein *et al.*
	AC2	5,672,611	09-30-1997	Doll *et al.*
	AD2	5,089,496	02-18-1992	Piwinski *et al.*
	AE2	5,302,602	04-12-1994	Oshima *et al.*
	AF2	5,302,596	04-12-1994	Oshima *et al.*
	AG2	5,143,922	09-01-1992	Oshima *et al.*
	AH2	5,242,931	09-07-1993	Oshima *et al.*
	AI2	5,118,701	04-23-1991	Oshima *et al.*
	AJ2	5,010,087	04-23-1991	Oshima *et al.*
	AK2	4,999,363	03-12-1991	Oshima *et al.*
	AA3	4,994,463	02-19-1991	Oshima *et al.*
	AB3	5,679,703	10-21-1997	Yanase *et al.*
	AC3	5,607,955	03-04-1997	Oshima *et al.*
	AD3	5,478,840	12-26-1995	Oshima *et al.*

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1855.2036-001	10/706,835	
	FIRST NAMED INVENTOR	FILING DATE	
June 14, 2004	Kenneth G. Carson	November 12, 2003	
(Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP
	Not assigned	6925	1616

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AE3	5,478,835	12-26-1995	Kumazawa *et al.*
	AF3	5,378,701	01-03-1995	Ohshima *et al.*
	AG3	5,340,807	08-23-1994	Kumazawa *et al.*
	AH3	5,239,083	08-24-1993	Kumazawa *et al.*
	AI3	5,116,863	05-26-1992	Ohshima *et al.*
	AJ3	4,547,496	10-15-1985	Kumazawa *et al.*
	AK3	3,409,621	11-05-1968	Villani *et al.*
	AA4	4,042,695	08-16-1977	Buss
	AB4	5,874,428	02-23-1999	Dorwald
	AC4	5,919,776	07-06-1999	Hagmann
	AD4	6,613,905	09-02-2003	Luly *et al.*
	AE4	6,509,346	01-21-2003	Luly *et al.*
	AF4	6,503,926	01-07-2003	Luly *et al.*
	AG4	6,433,165	08-13-2002	Luly *et al.*
	AH4	6,329,385	12-11-2001	Luly *et al.*
	AI4	6,288,084	09-11-2001	Luly *et al.*
	AJ4	6,288,083	09-11-2001	Luly *et al.*
	AK4	5,010,104	04-23-1991	Oshima *et al.*
	AA5	6,281,212 B1	08-28-2001	Schwender *et al*
	AB5	6,323,206 B1	11-27-2001	Schwender *et al.*
	AC5	US 2002/0169155 A1	11-14-2002	Luly, Jay R. *et al.*
	AD5	US 2003/0045516 A1	03-06-2003	Luly, Jay R. *et al.*

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1855.2036-001	APPLICATION NO. 10/706,835	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Kenneth G. Carson	FILING DATE November 12, 2003	
June 14, 2004	EXAMINER Not assigned	CONFIRMATION NO. 6925	GROUP 1616
(Use several sheets if necessary)			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AL	WO 98/11097	03-19-1998	Schering Corporation		
	AM	WO 98/11106	03-19-1998	Schering Corporation		
	AN	WO 97/44329	11-27-1997	Teijin Limited		
	AO	WO 98/04554	02-05-1998	Banyu Pharmaceutical Co., Ltd.		X
	AP	WO 98/27815	07-02-1998	Merck & Co., Inc.		
	AQ	WO 98/25604	06-18-1998	Merck & Co., Inc.		
	AL2	WO 98/25605	06-18-1998	Merck & Co., Inc.		
	AM2	WO 98/25617	06-18-1998	Merck & Co., Inc.		
	AN2	WO 89/10369	11-02-1989	Schering Corporation		
	AO2	WO 00/14086	03-16-2000	Leukosite, Inc.		
	AP2	WO 96/31498	10-10-1996	Novo Nordisk A/S		
	AQ2	DE 80449	09-25-1969	Kretzschmar, E. *et al.*	X	
	AL3	CZ 240 698	06-01-1987	Miroslav Protiva *et al.*		X
	AM3	WO 92/16226	10-01-1992	Smithkline Beecham Corporation		
	AN3	WO 99/37651	07-29-1999	Leukosite Inc.		
	AO3	WO 98/11099	03-19-1998	Schering Corporation		
	AP3	WO 98/11098	03-19-1998	Schering Corporation		
	AQ3	WO 98/11096	03-19-1998	Schering Corporation		
	AL4	WO 97/24325	07-10-1997	Takeda Chemical Industries, Ltd.		
	AM4	WO 98/11093	03-19-1998	Schering Corporation		
	AN4	WO 98/11092	03-19-1998	Schering Corporation		
	AO4	GB 1 003 292	09-02-1965	Ernst Jucker *et al.*		
	AP4	GB 1 330 966	09-19-1973	Yoshitomi Pharmaceutical Industries Ltd.		
	AQ4	CH 421 138	03-31-1967	Dr. A. Wander AG		X
	AL5	DE 1 918 739	10-20-1969	Egyesult Gyogyszer-es Tapszergyar		X

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1855.2036-001	10/706,835
	FIRST NAMED INVENTOR	FILING DATE
June 14, 2004	Kenneth G. Carson	November 12, 2003
(Use several sheets if necessary)	EXAMINER / CONFIRMATION NO. / GROUP	
	Not assigned / 6925 / 1616	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AM5	WO 98/15546	04-16-1998	Novo Nordisk A/S		
	AN5	WO 99/37617	07-29-1999	Leukosite, Inc.		
	AO5	WO 99/37619	07-29-1999	Leukosite, Inc.		
	AP5	WO 00/14089	03-16-2000	Leukosite, Inc.		
	AQ5	WO 93/02081	02-04-1993	Schering Corporation		
	AL6	WO 92/20681	11-26-1992	Schering Corporation		
	AM6	EP 0 916 668 A1	05-19-1999	Banyu Pharmaceutical Co., Ltd.		
	AN6	EP 0 309 422 A2	03-29-1989	Istituto De Angeli S.p.A.		
	AO6	JP 9-40662	02-10-1997	Kyowa Hakko Kogyo Co. Ltd.		X
	AP6	DE 33 26 641 A1	02-02-1984	BASF AG		X
	AQ6	JP 61 167663	07-29-1986	Otsuka Pharm Co Ltd		X
	AL7	GB 1109847	04-18-1968	Rhone-Poulenc S.A.		
	AM7	GB 1213172	11-18-1970	Fujisawa Pharmaceutical Co. Ltd.		
	AN7	WO 98/43638	10-08-1998	Kyowa Hakko Kogyo Co. Ltd.		X
	AO7	WO 98/46587	10-22-1998	Kyowa Hakko Kogyo Co. Ltd.		X
	AP7	WO 96/31477	10-10-1996	Schering Corporation		
	AQ7	WO 98/02151	01-22-1998	Leukosite, Inc.		
	AL8	EP 0 341 860 A1	11-15-1989	Schering Corporation		
	AM8	EP 0 515 158 A1	11-25-1992	Schering Corporation		
	AN8	EP 0 524 784 A1	01-27-1993	Schering Corporation		
	AO8	EP 0 270 692 A1	06-15-1988	Kyowa Hakko Kogyo Co. Ltd.		
	AP8	GB 1 013 574	12-15-1965	Spofa		
	AQ8	GB 1 003 950	09-08-1965	C.B. Boehringer & Soehne GmbH		
	AL9	GB 1 085 406	10-04-1967	Chas Pfizer and Co., Inc.		
	AM9	GB 1 206 216	09-23-1970	Chas Pfizer and Co., Inc.		

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1855.2036-001	10/706,835
	FIRST NAMED INVENTOR	FILING DATE
June 14, 2004	Kenneth G. Carson	November 12, 2003
	EXAMINER	CONFIRMATION NO. / GROUP
(Use several sheets if necessary)	Not assigned	6925 / 1616

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AN9	GB 1 347 935	02-27-1974	Yoshitomi Pharmaceutical Industries, Ltd.		
	AO9	EP 0 235 796 A2	09-09-1987	Kyowa Hokko Kogyo Co, Ltd.		
	AP9	EP 0 325 755 A1	02-08-1989	Kyowa Hokko Kogyo Co, Ltd.		
	AQ9	WO 00/32193 A1	06-08-2000	Novo Nordisk		
	AL10	WO 01/09094 A2	02-08-2001	Millennium Pharmaceuticals, Inc. *et al.*		
	AM10	WO 01/09119 A2	02-08-2001	Millennium Pharmaceuticals, Inc. *et al.*		
	AN10	WO 01/09137	02-08-2001	Millennium Pharmaceuticals, Inc. *et al.*		
	AO10	WO 01/09138	02-08-2001	Millennium Pharmaceuticals, Inc. *et al.*		
	AP10	WO 03/045942	06-05-2003	Millennium Pharmaceuticals, Inc. *et al.*		

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1855.2036-001	10/706,835	
	FIRST NAMED INVENTOR	FILING DATE	
June 14, 2004	Kenneth G. Carson	November 12, 2003	
(Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP
	Not assigned	6925	1616

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AR	Davis, M. A., *et al.,* "New Psychotropic Agents.VIII Analogs of Amitriptyline Containing Normeperidine Group," *J. Med. Chem.,* 10:627-635 (1967).
	AS	Helwig, H., *et al.,"* Helwig/Otto Arzneimittal, Ein Handbuch fur Arzte und Apotheker", pp. 4-1 through 4-24, 8th Ed., (1992).
	AT	Sindelar, Karel, *et al.*, "Potential Antidiarrheal Agents:1-(11-Cyano-6,11-Dihydrodibenzo[*b,e*]Thiepin-11yl-Alklyl)- and 1-(10-cyano-10,11-Dihydrodibenzo[*b,f*]Thiepin-10-YL-Alkyl)-4-Substituted Piperidines," *Collection Czechoslovak Chem. Commun.* 50:1089-1096 (1985).
	AU	Sindelar, K., *et al.*, Chemical Abstracts, 121:35275n (1994).
	AV	Sindelar, Karel, *et al.*, "Antihistamine Substances: Tricyclic Analogues of *N*-(4,4-Diphenyl-3Butene-1YL)Nipecotic Acid and Some Related Compounds," *Collection Czechoslovak Chem. Commun.* 59:667-674 (1994).
	AW	Ali, Fadia E., *et al.*, "Orally Active and Potent Inhibitors of γ-Aminobutyric Acid Uptake," *J. Med. Chem.* 28:653-660 (1985).
	AX	Sindelar, Karel, *et al.*, "Potential Antihistaminics: Tricyclic Carboxylic Acids Derived from 6,11-Dihydrodibenzo[*b,e*]Thiepine and 4,9-Dihydrothieno[2,3-*c*]-2-Benzothiepine," *Collection Czechoslovak Chem. Commun.* 56:2482-2493 (1991).
	AY	Polivka, Zdenek, *et al.*, "Heterocyclic Ethers Derived from 6,11-Dihydrodibenzo-[*b,e*]Thiepin-11-ols and 4,9-Dihydrothieno[2,3-*c*]-2-Benzothiepin-4-ol; A New Series of Potential Antidepressants and Antihistamine Agents," *Collection Czechoslovak Chem. Commun.* 51:2034-2049 (1986).
	AZ	Polivka, Zdenek, *et al.*, "Antiaminic Agents Derived from Thieno[2,3-*c*]-2-Benzothiepin: 4-(1-Methyl-4-Piperidylidene)-4,9-Dihydrothieno[2,3-*c*]-2-Benzothiepin and some Related Compounds," *Collection Czechoslovak Chem. Commun.* 48:623-641 (1983).
	AR2	Rajsner, M., *et al.*, "Neurotropic and Psychotropic Compounds. XXXI Chemistry and Pharmacology of 11-(3-Dimethylaminopropylidene)-2-Mehtyl-6,11-Dihydrodibenzo[*b,e*] Thiepin and of Some Analogues," *Collection Czechoslovak Chem. Commun.* 34:1015-1024 (1969).
	AS2	Rajsner, M., *et al.*, "Neurotrope and Psychotrope Substanzen XV. 4,9-Dihydrothieno[2,3-*b*]Benzo[*e*]Thiepin-Derivate," *Collection Czechoslovak Chem. Commun.* 32:2854-2866 (1967).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1855.2036-001	APPLICATION NO. 10/706,835	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Kenneth G. Carson	FILING DATE November 12, 2003	
June 14, 2004	EXAMINER Not assigned	CONFIRMATION NO. 6925	GROUP 1616
(Use several sheets if necessary)			

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AT2	Hesselgesser, Joseph, *et al.*, "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor", *The Journal of Biological Chemistry*, 273(25):15687-15692 (1998).
	AU2	Masaru, E. *et al.*, Chemical Abstracts, 93(19), 186323f (1980).
	AV2	Tsujikawa, T. *et al.*, Chemical Abstracts, 77(25), 164662h (1972).
	AW2	Nakanishi, M. *et al.* Chemical Abstracts, 81:25566Z (1974).
	AX2	Ting, P.C. *et al.*, Chemical Abstracts, 123:227838 (1995).
	AY2	Kumazawa, T. *et al.*, Chemical Abstracts, 126:212158 (1997).
	AZ2	Kato, K. *et al.*, Chemical Abstracts, 130:237480 (1999).
	AR3	Davis, M.A. *et al.*, Chemical Abstracts, 67:99959 (1967).
	AS3	Kukla, Michael J., Chemical Abstracts, 92:198282 (1980).
	AT3	Protiva, M. *et al.*, Chemical Abstracts, 72:3387 (1970).
	AU3	Protiva, M. *et al.*, Chemical Abstracts, 109:92794 (1988).
	AV3	Protiva, M. *et al.*, Chemical Abstracts, 104:19527 (1986).
	AW3	Protiva, M. *et al.*, Chemical Abstracts, 107:134327 (1987).
	AX3	Sindelar, K. *et al.*, Chemical Abstracts, 104:33990 (1986).
	AY3	Michaels, R.J. *et al.*, Chemical Abstracts, 77:88537 (1972).
	AZ3	Foldeak, S. *et al.*, Chemical Abstracts, 105:172012 (1986).
	AR4	Iorio, L.C. *et al.*, Chemical Abstracts, 115:126879 (1991).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1855.2036-001	APPLICATION NO. 10/706,835	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Kenneth G. Carson	FILING DATE November 12, 2003	
June 14, 2004	EXAMINER Not assigned	CONFIRMATION NO. 6925	GROUP 1616
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	AS4	Aftab, D.T. *et al.*, Chemical Abstracts, 116:120373 (1992).
	AT4	King, Frank D., "Bioisosteres, Conformational Restriction, and Pro-drugs-Case History: An Example of a Conformational Restriction Approach," *Medicinal Chemistry: Principles and Practice*, The Royal Society of Chemistry, London, 1995, Chapter 14, pp. 206-208.
	AU4	Foldeak, S. *et al.*, "The Mannich Reaction of 9-Acteyl- and 9, 10-Dihydro-9-Acetylanthracene. Reduction of the Mannich Bases, and Stereochemistry of the 9, 10-Dihydro Compounds," *Tetrahedron*, 41(24):5913-5918 (1985).
	AV4	Iorio, L.C. *et al.*, "Anticholinergic Drugs Potentiate Dopamine D1 but not D2 Antagonists on a Conditioned Avoidance Task in Rats," J. *Pharmacol. Exp. Ther.*, 258(1), 118-123 (1991).
	AW4	Aftab, D.T. *et al.*, "Structure-Activity Relationships of Phenothiazines and Related Drugs for Inhibition of Protein Kinase C," *Mol. Pharmacol.* 40(5):798-805 (1991).
	AX4	S.J. Rappaport, Ed., "Inflammation and Phagocytosis," In: *Pysiological Basis of Medical Practice, Twelfth Edition*, J.B. West, Eds., Williams & Wilkins, Baltimore, pp. 362-368 (1990).
	AY4	Schmelz, M. and Petersen, L.J., "Neurogenic Inflammation in Human and Rodent Skin," *News Physiol. Sci.*, 16:33-37 (2001).
	AZ4	Howard, O.M.Z. *et al.*, "Chemokines: Progress Toward Identifying Molecular Targets for Therapeutic Agents," TIBTECH., 14:46-51 (1996).
	AR5	Protiva, M. *et al.*, Chemical Abstracts, 107:134326 (1987).
	AS5	Oshima, E. *et al.*, Chemical Abstracts, 115:256025 (1991).

EXAMINER	DATE CONSIDERED